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Abstract: Galectin-3 has been implicated in the tumor development via its mediation of the Wnt signaling pathway. 
Likewise, glycogen synthase kinase-3beta (GSK3β) also plays a role in the Wnt signaling pathway by controlling the 
levels of cytoplasmic beta-catenin. Altered GSK3β expression has been described in various tumors, but to date, 
there are no studies evaluating its expression in models of oral carcinogenesis. Additionally, it is unknown whether 
the absence of galectin-3 regulates the expression of GSK3β. To this end, Gal3-deficient (Gal3-/-) and wild-type 
(Gal3+/+) male mice were treated with 4NQO for 16 weeks and sacrificed at week 16 and 32. The tongues were 
removed, processed, and stained with H&E to detect dysplasias and carcinomas. An immunohistochemical assay 
was performed to determine the level of P-GSK3β-Ser9 expression in both groups. Carcinomas were more prevalent 
in Gal3+/+ than Gal3-/- mice (55.5% vs. 28.5%), but no statistical difference was reached. In the dysplasias, the 
proportion of cells positive for P-GSK3β-Ser9 was slightly higher in Gal3+/+ than Gal3-/- mice (63% vs. 61%). In the 
carcinomas, a significant difference between Gal3+/+ and Gal3-/- mice was found (74% vs. 59%; p=0.02). P-GSK3β-
Ser9-positive cells slightly decreased from the progression of dysplasias to carcinomas in Gal3-/- mice (61% vs. 59%; 
p>0.05). However, a significant increase in P-GSK3β-Ser9 expression was observed from dysplasias to carcinomas 
in Gal3+/+ mice (63% vs. 74%; p=0.01). In conclusion, these findings suggest that fully malignant transformation of 
the tongue epithelium is associated with increased P-GSK3β-Ser9 expression in Gal3+/+ mice, but not in Gal3-/- mice.
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Introduction
Galectins are a mammalian family of lectins 
involved in various physiological and 
pathological processes [1, 2]. Among the 15 
recognized types of galectins, galectin-3 is one 
of the most widely studied [3]. As galectin-3 
has been implicated in a number of functions 
inside and outside the cells, including 
apoptosis, RNA splicing, cell proliferation, 
angiogenesis, cell adhesion, and survival, it is 
not surprising that it is involved with malignant 
transformation and tumor progression [4, 5]. 
Although the mechanism underlying its role in 
the tumor formation has not been firmly 
established, previous study shed light on this 
showing galectin-3 acting as a mediator of the 
Wnt signaling pathway [6]. Additionally, it was 
also recently reported that galectin-3 modulates 
the Wnt signaling pathway by regulating AKT 
phosphorylation levels and thus, GSK3β activity 
in human colon cancer cells [7]. 
It is well known that genes belonging to the Wnt 
signaling pathway play important roles in the 
development of a variety of malignancies [8]. 
Likewise, GSK3, a serine/threonine kinase and 
member of the Wnt signaling pathway, has 
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become one of the most attractive molecules 
because it exerts a wind spectrum of functions 
inside cells [9]. Despite presenting two 
isoforms, GSK3α and GSK3β, the latter is 
crucial in the regulation of diverse cellular 
functions, thereby its activity is much better 
characterized than the former [10]. About 
GSK3β, it phosphorylates a spectrum of 
proteins, including beta-catenin, a key member 
of the Wnt signaling pathway, driving it for 
degradation via ubiquitin-proteosome [9-11]. 
On the other hand, in the presence of a Wnt 
signal, GSK3β is inactivated and the level of 
beta-catenin is stabilized in the cytoplasm until 
its translocation into the nucleus, which is 
aided by galectin-3, to regulate transcriptional 
activity of some genes including c-myc and 
cyclin D1 [6].
It is widely accepted that GSK3β may cause 
malignant transformation by regulating a wide 
range of signaling pathways which in part are 
involved in different processes, including 
proliferation [11]. One possible explanation 
came from previous reports showing that 
phosphorylation of GSK3β on the Ser9 residue 
(P-GSK3β-Ser9) is implicated with tumor 
development by preventing phosphorylation 
and degradation of various proteins, and as a 
result leading to the activation of the signaling 
pathways [9, 12]. For example, in gastric 
carcinoma, high P-GSK3β-Ser9 expression was 
observed and correlated with vascular invasion, 
loco-regional metastasis, and tumoral staging 
[13]. Similarly, it was shown that P-GSK3β-Ser9 
expression is increased in colorectal 
carcinomas when compared to their benign 
counterparts [14]. However, whether P-GSK3β-
Ser9 is implicated with malignant transforma-
tion of oral tissues is unknown. 
We recently reported that absence of galec-
tin-3 is not critical for tongue-induced tumor in 
galectin-3-deficient mice (Gal3-/-), as was also 
shown by us in another study that Wnt signaling 
pathway was activated in dysplasias and 
carcinomas from both Gal3-/- and wild-type 
(Gal3+/+) mice [15, 16]. Here, trying to 
understand these previous findings, we ask 
whether P-GSK3β-Ser9, a negative regulator of 
the Wnt pathway and tumor inducer, whose 
activity is indirectly regulated by galectin-3 via 
AKT signaling, may be involved with malignant 
transformation of tongue epithelium. For this, 
we use the same approach previously reported, 
i.e., treating Gal3-/- and Gal3+/+ mice with the 
carcinogen 4-nitroquinoline-1-oxide (4NQO) to 
evaluate P-GSK3β Ser9 expression in 
dysplasias and carcinomas as a way to answer 
whether the number Gal3+/+ and Gal3-/- mice 
with tongue carcinomas were related with the 
level of this protein.
Material and methods
Animals 
The Committee on Animal Experimentation of 
the Universidade Federal de Uberlândia 
approved the use of the animals for the present 
study (CEUA/UFU # 038/09).
The Gal3-/- mice were designed and kindly 
provided the Hsu group [17]. Twenty male Gal3-/- 
mice at 6 weeks of age and weighing 23 g were 
used in this study. Another group of 20 Gal3+/+ 
mice with the same background were used as 
controls. Both groups of mice were split into 
two groups, which were sacrificed immediately 
after 4NQO treatment (at week 16; Gal3-/- n = 
10; Gal3+/+ n = 10) or 16 weeks after the end of 
4NQO treatment (at week 32; Gal3-/- n = 10; 
Gal3+/+ n = 10). All mice were maintained in 
controlled temperature (22°C) and light-dark 
periods of 12 h. All animals were permitted to 
have free access to a commercial diet. 
Experimental protocol
Treatment with the carcinogen 4NQO was 
based on the protocol described by Tang et al. 
[16]. 4NQO was initially diluted in propylene 
glycol (5 mg/ml) and then dissolved in filtered 
water to achieve a concentration of 100 µg/ml. 
The final solution was given to the mice for 16 
weeks in the drinking water ad libitum. 
Throughout the treatment period, the final 
solution was prepared weekly and administered 
for each group. At the end of the treatment, half 
the mice from Gal3+/+ and Gal3-/- groups were 
sacrificed immediately and the remaining were 
permitted to drink only filtered water until the 
euthanasia at week 32.
Microscopic examination
After ether anesthesia, all mice were killed by 
cervical dislocation after their lost 
GSK3β expression in tongue carcinomas of mice
549 Int J Clin Exp Pathol 2012;5(6):547-554
consciousness. The tongues from each mouse 
were removed and immediately fixed in 4% 
formalin for about 24 h. After this period, the 
tongues were cut transversely into five slices, 
routinely processed and embedded in paraffin. 
During this procedure, great care was taken by 
us when a lesion was observed on the tongue 
surface to avoid its omission in the microscopic 
view. In this case, the lesion was carefully cut to 
permit its representation on histological slide. 
Paraffin-embedded, 5-µm thick tissue sections 
were stained using a standard hematoxylin and 
eosin method to detect dysplasias and 
carcinomas according to the criteria established 
by Lumerman et al. [18] and Cardesa et al. [19], 
respectively. All histological slides were 
independently examined by three well-trained 
pathologists (PRF, AML, and SVC) to diagnose 
of the lesions. Discrepancies were solved after 
achieve a consensus scoring by the three 
pathologists. When two or more epithelial 
alterations were seen in the same histological 
slide, the highest aggressive lesion was taken 
to define the pathologic condition of the mouse.
Immunohistochemistry
A standard streptavidin-biotin peroxidase 
method using a polyclonal antibody to P-GSK3β-
Ser9 (Santa Cruz Biotechnology, USA; catalog 
number # sc-11757) was performed to evaluate 
its expression in the dysplasias and carcinomas 
from both groups of mice. Briefly, 3-µm thick 
tongue paraffin sections were mounted on 
silanized slides (Sigma Chemical Co, St Louis, 
MO, USA), deparaffinized in xylene and 
dehydrated in a series of decreasing 
concentrations of ethanol solution. Next, the 
tissue sections were submitted to antigen 
retrieval in 10 nM, pH 8.0 citric acid buffered 
saline solution using a pressure cooker for 4 
minutes. Subsequently, the tissue sections 
were treated with 3% hydrogen peroxide three 
times for 10 minutes each in order to block 
peroxidase activity. Following this, all tissues 
were washed once in tap and distilled water 
and then in phosphate buffered saline (10 mM, 
pH 7.4) for 10 minutes. The tissue sections 
were then incubated with a goat polyclonal anti-
body against P-GSK3β-Ser9 (1:200) diluted in 
PBS, 1% BSA and 0.1% sodium azide, for 30 
min at 37ºC and 18 h at 4ºC in a humid chamber. 
Next, the slides were rinsed three times for 3 
minutes each in PBS and incubated for 30 
minutes at 37ºC with a rabbit anti-goat IgG 
secondary antibody (Vector, CA, USA; catalog 
number # BA 5000) diluted at 1:500 and then 
with streptavidin-HRP complex (Dako, USA; 
catalog number # 377) at 1:200 for 30 minutes 
at 37ºC. After a PBS rinse, the reaction was 
then revealed with 3,3’-diaminobenzidine 
hydrochloride (Sigma, USA; catalog number # 
D-5637) diluted in 1 ml dimethyl sulfoxide and 
6% hydrogen peroxide for 5 minutes at room 
temperature followed by counterstaining with 
Harris hematoxylin. Lymph node sections were 
used as a positive control. The diluted primary 
antibody solution alone was used as a negative 
control.
Immunohistochemical staining was assessed 
through a standard method of cells-
quantification using the Image Processing and 
Analysis Software (Image J). To quantify the 
immunohistochemical staining, the ration of 
the number of labeled cells to the total number 
of cells was determined in the dysplasias and 
carcinomas from both groups of mice. The 
resulting index was expressed as the 
percentage of cytoplasmic and/or nuclear 
P-GSK3β-Ser9-positive cells in a median of 
800 cells counted. When two or more dysplasias 
were found in the same histological slide, the 
lesion of highest degree was chosen for 
immunohistochemical analysis. Likewise, when 
two or more carcinomas were observed in the 
same histological slide, the lesion with the 
higher horizontal dimension was chosen for 
immunohistochemical analysis. Furthermore, 
due to the small size of lesions, all the possible 
fields obtained for each lesion in the 400x 
magnification by light microscopic were taken 
for analysis.
Statistical analysis
Statistical analysis of the incidence of 
dysplasias and carcinomas between Gal3+/+ 
and Gal3-/- mice was performed using Fisher’s 
exact test. The mean index of positive cells 
between dysplastic lesions and carcinomas 
from Gal3+/+ and Gal3-/- mice was determined 
using the Mann-Whitney non-parametric test. 
All data were analyzed using GraphPad Prism 
software (San Diego, USA, version 5.0). All 
values were expressed as means ± standard 
deviation, and a value of p<0.05 was considered 
statistically significant.
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Results
Unfortunately, 2 of the Gal3+/+ mice and 6 of the 
Gal3-/- mice died prior to the end of the experi-
ment and were thus excluded from the results 
of this study. However, the causa mortis could 
not be determined because of autolysis of tis-
sues on microscopic view.
The data from the carcinogenesis could be seen 
elsewhere [16]. In summary, the oral carcino-
genesis occurred in both groups. Overall, 55.5% 
of the Gal3+/+ mice developed tongue carcino-
mas, while only 28.5% of the Gal3-/- group 
developed carcinomas. However, no statistical 
difference could be achieved, suggesting that 
absence of galectin-3 does not affect the malig-
nant transformation of the tongue epithelial 
cells in mice.
Immunohistochemistry
The immunostaining for P-GSK3β-Ser9 in the 
samples of dysplasias and carcinomas from 
Gal3+/+ and Gal3-/- mice is shown in Figure 1.
To evaluate whether the absence of galectin-3 
influences the expression of P-GSK3β-Ser9 in 
this model of carcinogenesis, a standard immu-
nohistochemistry protocol was used. P-GSK3β-
Ser9 immunostaining was quantified in the dys-
plastic lesions of highest degree and/or the 
tongue carcinomas with the highest horizontal 
dimension in the histological sections from the 
mice, as aforementioned. In the dysplasias, the 
mean index of cells positive for P-GSK3β-Ser9 
was slightly higher in Gal3+/+ than Gal3-/- mice 
(63±12% vs. 61±16%; respectively) with no 
statistical difference reached (Figure 2A). In 
the carcinomas, the percentage of P-GSK3β-
Ser9-positive cells was significantly higher in 
Gal3+/+ than Gal3-/- mice (74±6% vs. 59±19%, 
respectively) (Figure 2B). In the intragroup anal-
ysis, a statistical difference between the dys-
plasias and carcinomas from Gal3+/+ mice was 
determined (p=0.01), but not when the same 
analysis was applied to the lesions in Gal3-/- 
mice (Figure 2C and 2D). Taken together, these 
data suggest a possible role for P-GSK3β-Ser9 
in the malignant transformation of lingual epi-
thelium of Gal3+/+ mice as well as the high inci-
dence of carcinomas in this group when com-
pared to Gal3-/- mice. 
Discussion
Carcinogenesis is a multistep process that 
occurs due to a progressive accumulation of 
Figure 1. Immunostaining for P-GSK3β-Ser9. A. Dysplasia from Gal3+/+ mice presenting a specific nuclear expres-
sion. (B and C) Carcinoma from Gal3+/+ mice. As in the dysplasia, a nuclear expression inside tumor cells was 
observed. D. Dysplastic lesion from Gal3-/- mice showing a nuclear expression. (E and F) Carcinoma from Gal3-/- 
mice exhibiting a nuclear expression in the tumor cells. Magnification lens is x200 for a and d, x100 for b and e, 
and x400 for c and f.
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genetic alterations that drives cells to an onco-
genic phenotype [20]. There are countless ani-
mal models of carcinogenesis, and all are 
intended to develop lesions similar to those 
that occur in humans [21, 22]. One of these 
models is based on the ingestion of carcino-
genic substances by rodents for a period of 
time. All of the substances employed in these 
experimental models, 7, 12-dimethylbenz(a)
anthracene (DMBA) and 4NQO are the most 
widely used [23]. Although chemically different, 
both compounds have mutagenic and carcino-
genic effects and induce epithelial changes in a 
similar way as observed in the oral carcinogen-
esis in humans [24]. Here, we use a mouse 
model of carcinogenic induction described by 
Tang et al., who administered 4NQO diluted in 
propylene glycol for 16 weeks [21]. As observed 
by them, in our study premalignant lesions and 
carcinomas developed in the tongues from 
Gal3+/+ and Gal3-/- mice, indicating that this 
model is a reliable and effective approach to 
study oral carcinogenesis.
We did not observe any difference in the inci-
dence of dysplasias and carcinomas between 
Gal3+/+ and Gal3-/- mice. Overall, the percent-
age of Gal3+/+ mice with carcinoma was higher 
than Gal3-/- mice (55.5% vs. 28.5%). Besides, 
while approximately 89% of Gal3+/+ mice devel-
oped tumors at week 32, only 50% of Gal3-/- 
Gal3+/+ and Gal3-/- mice at the end of week 32 
(p <0.05) [25]. In contrast, we recently showed 
that the absence of galectin-3 is not consid-
ered an important mediator of tongue carcino-
genesis in mice [15]. Similar conclusions have 
been reported by Eude-Le Parco et al. [26] who 
using galectin-3 null mice, revealed that galec-
tin-3 is not pivotal in the promotion of lung 
tumorigenesis [26]. Previous studies have 
shown that galectin-3 is strikingly important in 
diverse biological processes inside cells and 
therefore, its disruption has the potential to 
drive cells to malignant transformation ([1]. Of 
particular interest, studies showing the involve-
ment of galectin-3 in the Wnt signaling pathway 
have enlightened some aspects of its tumor-
inducing role [1, 6, 27, 28]. Although our results 
highlight the idea stated by us in another study, 
namely, that galectin-3 does not exert any role 
in the development of tongue carcinomas in 
mice, we cannot completely exclude a possible 
association between increased incidence of 
tumors and more activated Wnt signaling path-
way in Gal3+/+ mice than in Gal3-/- mice, as 
recently described by us and another group 
[15, 16, 25]. 
In line with this observation, we sought to eval-
uate the expression of the inactive form of 
GSK3β, P-GSK3β-Ser9, in dysplasias and carci-
nomas developed from Gal3+/+ and Gal3-/- mice 
mice did. Different 
results were report-
ed by Abdel-Aziz et 
al. [25] who found a 
difference statisti-
cally significant in 
the incidence of lung 
tumors between 
Figure 2. Mean index 
of cells positive for 
P-GSK3β-Ser9. (A and 
B) Comparative analy-
sis between dyspla-
sias and carcinomas 
developed in Gal3+/+ 
and Gal3-/- mice. C. 
Comparative analysis 
between dysplasias 
and carcinomas from 
Gal3+/+ mice. D. Com-
parative analysis be-
tween dysplasias and 
carcinomas from Gal3-
/- mice.
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ing pathway but also because of the presence 
of galectin-3 in the oral tissues from Gal3+/+ 
mice, instead of Gal3-/- mice. 
In conclusion, up-regulation of the inactive form 
of GSK3β is associated with malignant trans-
formation of the tongue epithelium of Gal3+/+ 
mice. However, our results do not permit to 
state a complete lack of GSK3β activity in the 
tongue from Gal3-/- mice because P-GSK3β-
Ser9-positive cells were observed in the dys-
plasias and carcinomas from this group, which 
seems to indicate the involvement of another 
signaling pathway in the regulation of this pro-
tein in this group. On the other hand, it is 
unknown whether the highest level of P-GSK3β-
Ser9 expression in Gal3+/+-developed carcino-
mas is linked with the elevated expression of 
others Wnt target proteins, such as cyclin D1 
and c-myc, which need to be elucidate. Lastly, 
further studies are warranted to enlighten the 
mechanism governing the difference in 
P-GSK3β-Ser9 expression between Gal3+/+ and 
Gal3-/- mice and how that expression is promot-
ing the neoplastic transformation of tongue epi-
thelium differently between the groups of mice.
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